Patents by Inventor Yue-Mei Zhang

Yue-Mei Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors
    Patent number: 10961293
    Abstract: The present invention comprises compounds of Formula I. wherein: Z4, Z7, Z9, Z11, Z22, Z23, Z26, Z30, Z34, Z35, p, m, n, q, and BRIDGE are defined in the specification. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel compounds are useful for preventing, treating or ameliorating diseases and disorders, such as obesity, type 2 diabetes, the metabolic syndrome, insulin resistance, and dyslipidemia, among others.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: March 30, 2021
    Assignee: Janssen Pharmaceutics NV
    Inventors: Mark Macielag, Raymond J. Patch, Rui Zhang, Martin A. Case, Mark J. Wall, Yue-Mei Zhang
  • Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof
    Patent number: 10875902
    Abstract: The present invention comprises conjugates comprising a glucagon-like peptide 1 (GLP-1) fusion peptide coupled to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: December 29, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Yue-Mei Zhang, Raul C. Camacho, Martin A. Case, Ellen Chi, Suzanne Edavettal, Wilson Edwards, Lisa Norquay, Mark J. Wall, Rui Zhang, Songmao Zheng
  • IMMUNOGLOBULINS AND USES THEREOF
    Publication number: 20200385439
    Abstract: The present invention relates to a monoclonal antibody platform designed to be coupled to therapeutic peptides to increase the half-life of the therapeutic peptide in a subject. The invention also relates to pharmaceutical compositions and methods for use thereof.
    Type: Application
    Filed: August 21, 2020
    Publication date: December 10, 2020
    Inventors: Mark MACIELAG, Raymond J. Patch, Rui Zhang, Martin A. Case, Shamina M. Rangwala, James N. Leonard, Raul C. Camacho, Michael J. Hunter, Katharine E. D'Aquino, Wilson Edwards, Ronald V. Swanson, Wenying Jian, Yue-Mei Zhang, Mark J. Wall, Ellen Chi
  • Immunoglobulins and uses thereof
    Patent number: 10858413
    Abstract: The present invention relates to a monoclonal antibody platform designed to be coupled to therapeutic peptides to increase the half-life of the therapeutic peptide in a subject. The invention also relates to pharmaceutical compositions and methods for use thereof.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: December 8, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Mark Macielag, Raymond J. Patch, Rui Zhang, Martin A. Case, Mark J. Wall, Yue-Mei Zhang, Shamina M. Rangwala, James N. Leonard, Raul C. Camacho, Michael J. Hunter, Katharine E. D'Aquino, Wilson Edwards, Ronald V. Swanson, Wenying Jian, Ellen Chi
  • Immunoglobulins and uses thereof
    Patent number: 10787495
    Abstract: The present invention relates to a monoclonal antibody platform designed to be coupled to therapeutic peptides to increase the half-life of the therapeutic peptide in a subject. The invention also relates to pharmaceutical compositions and methods for use thereof.
    Type: Grant
    Filed: August 16, 2019
    Date of Patent: September 29, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Mark Macielag, Raymond J. Patch, Rui Zhang, Martin A. Case, Shamina M. Rangwala, James N. Leonard, Raul C. Camacho, Michael J. Hunter, Katharine E. D'Aquino, Wilson Edwards, Ronald V. Swanson, Wenying Jian, Yue-Mei Zhang, Mark J. Wall, Ellen Chi
  • ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS
    Publication number: 20200283491
    Abstract: The present invention comprises conjugates comprising a monoclonal antibody conjugated to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.
    Type: Application
    Filed: March 16, 2020
    Publication date: September 10, 2020
    Inventors: Mark MACIELAG, Raymond J. PATCH, Rui ZHANG, Martin A. CASE, Shamina M. RANGWALA, James N. LEONARD, Raul C. CAMACHO, Michael J. HUNTER, Katharine E. D'AQUINO, Wilson EDWARDS, Ronald V. SWANSON, Wenying JIAN, Yue-Mei ZHANG, Mark J. WALL, Ellen CHI
  • Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes
    Patent number: 10662170
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R5, R6, W, and A are defined herein.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: May 26, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Hui Huang, Gee-Hong Kuo, Mark R. Player, Shyh-Ming Yang, Yue-Mei Zhang
  • Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors
    Patent number: 10640544
    Abstract: The present invention comprises conjugates comprising a monoclonal antibody conjugated to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: May 5, 2020
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Mark Macielag, Raymond J Patch, Rui Zhang, Martin A Case, Shamina M Rangwala, James N Leonard, Raul C Camacho, Michael J Hunter, Katharine E. D'Aquino, Wilson Edwards, Ronald V Swanson, Wenying Jian, Yue-Mei Zhang, Mark Wall, Ellen Chi
  • IMMUNOGLOBULINS AND USES THEREOF
    Publication number: 20190367577
    Abstract: The present invention relates to a monoclonal antibody platform designed to be coupled to therapeutic peptides to increase the half-life of the therapeutic peptide in a subject. The invention also relates to pharmaceutical compositions and methods for use thereof.
    Type: Application
    Filed: August 16, 2019
    Publication date: December 5, 2019
    Inventors: Mark MACIELAG, Raymond J. PATCH, Rui ZHANG, Martin A. CASE, Shamina M. RANGWALA, James N. LEONARD, Raul C. CAMACHO, Michael J. HUNTER, Katharine E. D'AQUINO, Wilson EDWARDS, Ronald V. SWANSON, Wenying JIAN, Yue-Mei ZHANG, Mark J. WALL, Ellen CHI
  • CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS
    Publication number: 20190345214
    Abstract: The present invention comprises compounds of Formula I. wherein: Z4, Z7, Z9, Z11, Z22, Z23, Z26, Z30, Z34, Z35, p, m, n, q, and BRIDGE are defined in the specification. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel compounds are useful for preventing, treating or ameliorating diseases and disorders, such as obesity, type 2 diabetes, the metabolic syndrome, insulin resistance, and dyslipidemia, among others.
    Type: Application
    Filed: October 26, 2017
    Publication date: November 14, 2019
    Inventors: Mark MACIELAG, Raymond J. PATCH, Rui ZHANG, Martin A. CASE, Mark J. WALL, Yue-Mei ZHANG
  • GLUCAGON LIKE PEPTIDE 1 (GLP-1) FUSION PEPTIDE COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE CONJUGATES AND USES THEREOF
    Publication number: 20190330296
    Abstract: The present invention comprises conjugates comprising a glucagon-like peptide 1 (GLP-1) fusion peptide coupled to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.
    Type: Application
    Filed: April 24, 2019
    Publication date: October 31, 2019
    Inventors: Yue-Mei ZHANG, Raul C. CAMACHO, Martin A. CASE, Ellen CHI, Suzanne EDAVETTAL, Wilson EDWARDS, Lisa NORQUAY, Mark J. WALL, Rui ZHANG, Songmao ZHENG
  • ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS
    Publication number: 20190298849
    Abstract: The present invention comprises conjugates comprising a monoclonal antibody conjugated to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.
    Type: Application
    Filed: October 26, 2017
    Publication date: October 3, 2019
    Inventors: Mark MACIELAG, Raymond J. PATCH, Rui ZHANG, Martin A. CASE, Shamina M. RANGWALA, James N. LEONARD, Raul C. CAMACHO, Michael J. HUNTER, Katharine E. D'AQUINO, Wilson EDWARDS, Ronald V. SWANSON, Wenying JIAN, Yue-Mei ZHANG, Mark J. WALL, Ellen CHI
  • Immunoglobulins and uses thereof
    Patent number: 10428134
    Abstract: The present invention relates to a monoclonal antibody platform designed to be coupled to therapeutic peptides to increase the half-life of the therapeutic peptide in a subject. The invention also relates to pharmaceutical compositions and methods for use thereof.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: October 1, 2019
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Mark Macielag, Raymond J Patch, Rui Zhang, Martin A Case, Shamina M Rangwala, James N Leonard, Raul C Camacho, Michael J Hunter, Katharine E. D'Aquino, Wilson Edwards, Ronald V Swanson, Wenying Jian, Yue-Mei Zhang, Mark Wall, Ellen Chi
  • IMMUNOGLOBULINS AND USES THEREOF
    Publication number: 20190263879
    Abstract: The present invention relates to a monoclonal antibody platform designed to be coupled to therapeutic peptides to increase the half-life of the therapeutic peptide in a subject. The invention also relates to pharmaceutical compositions and methods for use thereof.
    Type: Application
    Filed: October 26, 2017
    Publication date: August 29, 2019
    Inventors: Mark MACIELAG, Raymond J. PATCH, Rui ZHANG, Martin A. CASE, Mark J. WALL, Yue-Mei ZHANG, Shamina M. RANGWALA, James N. LEONARD, Raul C. CAMACHO, Michael J. HUNTER, Katharine E. D'AQUINO, Wilson EDWARDS, Ronald V. SWANSON, Wenying JIAN, Ellen CHI
  • SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES
    Publication number: 20190062300
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R5, R6, W, and A are defined herein.
    Type: Application
    Filed: October 30, 2018
    Publication date: February 28, 2019
    Inventors: Hui Huang, Gee-Hong Kuo, Mark R. Player, Shyh-Ming Yang, Yue-Mei Zhang
  • BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS
    Publication number: 20190031618
    Abstract: The present invention is directed to benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions mediated by the CB-1 receptor, more particularly, use in the treatment of disorders and conditions responsive to inverse agonism of the CB-1 receptor. More particularly, the compounds of the present invention are useful in the treatment of metabolic disorders.
    Type: Application
    Filed: October 3, 2018
    Publication date: January 31, 2019
    Applicant: Janssen Pharmaceutica NV
    Inventors: Mark J. Macielag, Rui Zhang, Yue-Mei Zhang, Bin Zhu, Michael H. Parker, Donald W. Ludovici, Daniel J. Parks, Bart L. DeCorte, Michael N. Greco
  • Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes
    Patent number: 10131648
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R5, R6, W, and A are defined herein.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: November 20, 2018
    Assignee: Janssen Pharmaceutica NV
    Inventors: Hui Huang, Gee-Hong Kuo, Mark R. Player, Shyh-Ming Yang, Yue-Mei Zhang
  • Benzimidazole derivatives useful as CB-1 inverse agonists
    Patent number: 10118900
    Abstract: The present invention is directed to benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions mediated by the CB-1 receptor; more particularly, use in the treatment of disorders and conditions responsive to inverse agonism of the CB-1 receptor. More particularly, the compounds of the present invention are useful in the treatment of metabolic disorders.
    Type: Grant
    Filed: August 23, 2016
    Date of Patent: November 6, 2018
    Assignee: Janssen Pharmaceutica NV
    Inventors: Mark J. Macielag, Rui Zhang, Yue-Mei Zhang, Bin Zhu, Michael H. Parker, Donald W. Ludovici, Daniel J. Parks, Bart L. DeCorte, Michael N. Greco
  • IMMUNOGLOBULINS AND USES THEREOF
    Publication number: 20180125998
    Abstract: The present invention relates to a monoclonal antibody platform designed to be coupled to therapeutic peptides to increase the half-life of the therapeutic peptide in a subject. The invention also relates to pharmaceutical compositions and methods for use thereof.
    Type: Application
    Filed: October 26, 2017
    Publication date: May 10, 2018
    Inventors: Mark Macielag, Raymond J. Patch, Rui Zhang, Martin A. Case, Shamina M. Rangwala, James N. Leonard, Raul C. Camacho, Michael J. Hunter, Katharine E. D'Aquino, Wilson Edwards, Ronald V. Swanson, Wenying Jian, Yue-Mei Zhang, Mark Wall, Ellen Chi
  • CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS
    Publication number: 20180127476
    Abstract: The present invention comprises compounds of Formula I. wherein: Z4, Z7, Z9, Z11, Z22, Z23, Z26, Z30, Z34, Z35, p, m, n, q, and BRIDGE are defined in the specification. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel compounds are useful for preventing, treating or ameliorating diseases and disorders, such as obesity, type 2 diabetes, the metabolic syndrome, insulin resistance, and dyslipidemia, among others.
    Type: Application
    Filed: October 26, 2017
    Publication date: May 10, 2018
    Inventors: Mark Macielag, Raymond J. Patch, Rui Zhang, Martin A. Case, Yue-Mei Zhang, Mark Wall